Results-driven healthcare professional with 5 years of experience in research, strategy development, and market access. Proven track record of developing and executing successful market access strategies to optimize product value, drive market penetration, and ensure patient access to innovative therapies. Excel at leveraging data-driven insights to interpret market trends, develop value propositions, and targeted solutions for client products. Skilled in independently handling client meetings and addressing challenging inquiries with precision and professionalism. Experienced in leadership roles, providing guidance and mentorship to colleagues, including senior team members. Committed to driving positive outcomes for patients and stakeholders. Seeking a position that challenges me to further develop leadership skills and contribute to a dynamic environment focused on optimizing healthcare outcomes, market access, and product/brand development.
Champion D, Suthen S, Jha A, Bourcet A. Value of In-vitro diagnostics in APAC: Value Assessment Framework with Applications for Coronary Artery Disease and Heart Failure [Internet]. 2023.
Suthen, S., Lim, C. J., Nguyen, P. H., Dutertre, C., Lai, H. L., Wasser, M., … Chew, V. (2022). Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC. Hepatology, 76(5), 1329–1344. doi:10.1002/hep.32419
Nguyen, P. H., Wasser, M., Tan, C. T., Lim, C. J., Lai, H. L., Seow, J. J., DasGupta, R., Phua, C. Z., Ma, S., Yang, J., Suthen, S.,… Chew, V. (2022). Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. Nature Communications, 13(1). https://doi.org/10.1038/s41467022-29122-w
Chuah, S., Lee, J., Song, Y., Kim, H.-D., Wasser, M., Kaya, N. A., Bang, K., Lee, Y. J., Jeon, S. H., Suthen, S., … Chew, V. (2022). Uncoupling immune trajectories of response and adverse events from anti-PD-1 Immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 77(3), 683–694.
https://doi.org/10.1016/j.jhep.2022.03.039